Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence
Abstract
:1. Introduction
2. Materials and Methods
Search of Scientific Literature
3. SARS-CoV-2
4. Therapeutic Potential of Medicinal Plants
5. Phytochemicals as Potential Therapeutics in SARS-CoV-2 Virus Infection
5.1. Quercetin
5.2. Curcumin
5.3. Baicalin
5.4. Kaempferol
5.5. Resveratrol
5.6. Glycyrrhizin
5.7. Lycorine
5.8. Colchicine
5.9. Artemisinin
6. The Effectiveness of Phytotherapeutics—Proven by Clinical Research
7. Future Prospects
8. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sunday, R.M. Acclaimed Medicinal Plants Used for the Prevention and Treatment of Coronavirus Disease 2019: Concerns on Safety Levels. Innovare J. Med. Sci. 2021, 9, 9–11. [Google Scholar]
- Mirzaie, A.; Halaji, M.; Dehkordi, F.S.; Ranjbar, R.; Noorbazargan, H. A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). Complementary Ther. Clin. Pract. 2020, 40, 101214. [Google Scholar] [CrossRef] [PubMed]
- Ludwig, S.; Zarbock, A. Coronaviruses and SARS-CoV-2: A brief overview. Anesth. Analg. 2020, 131, 93–96. [Google Scholar] [CrossRef] [PubMed]
- Bahadur, S.; Long, W.; Shuaib, M. Human coronaviruses with emphasis on the COVID-19 outbreak. Virusdisease 2020, 31, 80–84. [Google Scholar] [CrossRef] [PubMed]
- Kadam, S.B.; Sukhramani, G.S.; Bishnoi, P.; Pable, A.A.; Barvkar, V.T. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. J. Basic Microbiol. 2021, 61, 180–202. [Google Scholar] [CrossRef]
- Yin, Y.; Wunderink, R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018, 23, 130–137. [Google Scholar] [CrossRef] [Green Version]
- Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [Green Version]
- Yadav, A.; Mohite, S. A Review on Novel Coronavirus (COVID-19). Int. J. Pharma Sci. Res. 2020, 11, 76. [Google Scholar]
- Khadka, D.; Dhamala, M.K.; Li, F.; Aryal, P.C.; Magar, P.R.; Bhatta, S.; Thakur, M.S.; Basnet, A.; Cui, D.; Shi, S. The use of medicinal plants to prevent COVID-19 in Nepal. J. Ethnobiol. Ethnomedicine 2021, 17, 1–17. [Google Scholar] [CrossRef]
- Yadav, V.; Kaushik, P. Phytochemicals against COVID-19 and a gap in clinical investigations: An outlook. Indian J. Biochem. Biophys. (IJBB) 2021, 58, 403–407. [Google Scholar]
- Khanna, K.; Kohli, S.K.; Kaur, R.; Bhardwaj, A.; Bhardwaj, V.; Ohri, P.; Sharma, A.; Ahmad, A.; Bhardwaj, R.; Ahmad, P. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle. Phytomedicine 2021, 85, 153361. [Google Scholar] [CrossRef] [PubMed]
- Acedhars Unilag COVID-19 Response Team; Akindele, A.J.; Agunbiade, F.O.; Sofidiya, M.O.; Awodele, O.; Sowemimo, A.; Ade-Ademilua, O.; Akinleye, M.O.; Ishola, I.O.; Orabueze, I.; et al. COVID-19 pandemic: A case for phytomedicines. Nat. Prod. Commun. 2020, 15, 1934578X20945086. [Google Scholar]
- Khan, S.; Siddique, R.; Shereen, M.A.; Ali, A.; Liu, J.; Bai, Q.; Bashir, N.; Xue, M. Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: Biology and therapeutic options. J. Clin. Microbiol. 2020, 58, e00187-20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Benarba, B.; Pandiella, A. Medicinal plants as sources of active molecules against COVID-19. Front. Pharmacol. 2020, 11, 1189. [Google Scholar] [CrossRef]
- Su, S.; Wong, G.; Shi, W.; Liu, J.; Lai, A.C.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016, 24, 490–502. [Google Scholar] [CrossRef] [Green Version]
- Del Rio, R.; Marcus, N.J.; Inestrosa, N.C. Potential role of autonomic dysfunction in Covid-19 morbidity and mortality. Front. Physiol. 2020, 11, 561749. [Google Scholar] [CrossRef]
- Van Boheemen, S.; De Graaf, M.; Lauber, C.; Bestebroer, T.M.; Raj, V.S.; Zaki, A.M.; Osterhaus, A.D.M.E.; Haagmans, B.L.; Gorbalenya, A.E.; Snijder, E.J. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012, 3, e00473-12. [Google Scholar] [CrossRef] [Green Version]
- Anand, A.V.; Balamuralikrishnan, B.; Kaviya, M.; Bharathi, K.; Parithathvi, A.; Arun, M.; Senthilkumar, N.; Velayuthaprabhu, S.; Saradhadevi, M.; Al-Dhabi, N.A. Medicinal plants, phytochemicals, and herbs to combat viral pathogens including SARS-CoV-2. Molecules 2021, 26, 1775. [Google Scholar] [CrossRef]
- Mousavizadeh, L.; Ghasemi, S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J. Microbiol. Immunol. Infect. 2021, 54, 159–163. [Google Scholar] [CrossRef]
- Malik, Y.S.; Sircar, S.; Bhat, S.; Sharun, K.; Dhama, K.; Dadar, M.; Tiwari, R.; Chaicumpa, W. Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. Vet. Q. 2020, 40, 68–76. [Google Scholar] [CrossRef]
- Dousari, A.S.; Moghadam, M.T.; Satarzadeh, N. COVID-19 (Coronavirus disease 2019): A new coronavirus disease. Infect. Drug Resist. 2020, 13, 2819. [Google Scholar] [CrossRef] [PubMed]
- Uzunian, A. Coronavirus SARS-CoV-2 and COVID-19. J. Bras Patol. Med. Lab. 2020, 56, 1–4. [Google Scholar] [CrossRef]
- Akram, A.; Mannan, N. Molecular structure, pathogenesis and virology of SARS-CoV-2: A review. Bangladesh J. Infect. Dis. 2020, 7, S36–S40. [Google Scholar] [CrossRef]
- Adekola, H.A.; Adekunle, I.; Alabi-Abass, M.; Ogunbanjo, W.; Ajewole, I. Phytotherapeutic potential of herbal supplements for COVID-19. Arab. J. Med. Aromat. Plants 2021, 7, 304–320. [Google Scholar]
- Jackson, C.B.; Farzan, M.; Chen, B.; Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022, 23, 3–20. [Google Scholar] [CrossRef]
- Tian, S.; Hu, W.; Niu, L.; Liu, H.; Xu, H.; Xiao, S.-Y. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J. Thorac. Oncol. 2020, 15, 700–704. [Google Scholar] [CrossRef]
- Jin, Y.-H.; Cai, L.; Cheng, Z.-S.; Cheng, H.; Deng, T.; Fan, Y.-P.; Fang, C.; Huang, D.; Huang, L.Q.; Huang, Q. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil. Med. Res. 2020, 7, 1–23. [Google Scholar] [CrossRef] [Green Version]
- Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K.S.M.; Lau, E.H.Y.; Wong, J.Y. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N. Engl. J. Med. 2020, 382, 1199–1207. [Google Scholar] [CrossRef]
- Wang, Y.; Kang, H.; Liu, X.; Tong, Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol. 2020, 92, 538–539. [Google Scholar] [CrossRef] [Green Version]
- Carlos, W.G.; Dela Cruz, C.S.; Cao, B.; Pasnick, S.; Jamil, S. Novel Wuhan (2019-nCoV) Coronavirus. Am. J. Respir. Crit. Care Med. 2020, 2020, P7–P8. [Google Scholar] [CrossRef] [Green Version]
- Prompetchara, E.; Ketloy, C.; Palaga, T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol. 2020, 38, 1–9. [Google Scholar] [PubMed]
- Shang, Y.; Pan, C.; Yang, X.; Zhong, M.; Shang, X.; Wu, Z.; Yu, Z.; Zhang, W.; Zhong, Q.; Zheng, X. Management of critically ill patients with COVID-19 in ICU: Statement from front-line intensive care experts in Wuhan, China. Ann. Intensive Care 2020, 10, 1–24. [Google Scholar] [CrossRef] [PubMed]
- Ernst, E. The role of complementary and alternative medicine. BMJ 2000, 321, 1133. [Google Scholar] [CrossRef] [Green Version]
- Organization WHO. WHO Global Report on Traditional and Complementary Medicine 2019; World Health Organization: Geneva, Switzerland, 2019.
- Ganjhu, R.K.; Mudgal, P.P.; Maity, H.; Dowarha, D.; Devadiga, S.; Nag, S.; Arunkumar, G. Herbal plants and plant preparations as remedial approach for viral diseases. Virusdisease 2015, 26, 225–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hwang, J.R.; Cartron, A.M.; Khachemoune, A. A review of Nigella sativa plant-based therapy in dermatology. Int. J. Dermatol. 2021, 60, e493–e499. [Google Scholar] [CrossRef] [PubMed]
- Akbaş, M.; Akcakaya, A. COVID-19 and Phytotherapy. Bezmialem Sci. 2020, 8, 51–75. [Google Scholar] [CrossRef]
- Khan, S.A.; Al-Balushi, K. Combating COVID-19: The role of drug repurposing and medicinal plants. J. Infect. Public Health 2021, 14, 495–503. [Google Scholar] [CrossRef] [PubMed]
- Sytar, O.; Brestic, M.; Hajihashemi, S.; Skalicky, M.; Kubeš, J.; Lamilla-Tamayo, L.; Ibrahimova, U.; Ibadullayeva, S.; Landi, M. COVID-19 prophylaxis efforts based on natural antiviral plant extracts and their compounds. Molecules 2021, 26, 727. [Google Scholar] [CrossRef]
- Aydin, D.Y.; Gürü, S. Potential of Natural Therapeutics Against SARS-CoV-2: Phenolic Compounds and Terpenes; Nam. Kem. Med. J. 2022, 10, 119–128. [Google Scholar]
- Merarchi, M.; Dudha, N.; Das, B.C.; Garg, M. Natural products and phytochemicals as potential anti-SARS-CoV-2 drugs. Phytother. Res. 2021, 35, 5384–5396. [Google Scholar] [CrossRef]
- Sasidharan, S.; Chen, Y.; Saravanan, D.; Sundram, K.; Latha, L.Y. Extraction, isolation and characterization of bioactive compounds from plants’ extracts. Afr. J. Tradit. Complementary Altern. Med. 2011, 8, 1–10. [Google Scholar] [CrossRef] [Green Version]
- Hermel, M.; Sweeney, M.; Ni, Y.-M.; Bonakdar, R.; Triffon, D.; Suhar, C.; Mehta, S.; Dalhoumi, S.; Gray, J. Natural Supplements for COVID19—Background, Rationale, and Clinical Trials. J. Evid. -Based Integr. Med. 2021, 26, 2515690X211036875. [Google Scholar] [CrossRef] [PubMed]
- Di Pierro, F.; Iqtadar, S.; Khan, A.; Mumtaz, S.U.; Chaudhry, M.M.; Bertuccioli, A.; Derosa, G.; Maffioli, P.; Togni, S.; Riva, A. Potential clinical benefits of quercetin in the early stage of COVID-19: Results of a second, pilot, randomized, controlled and open-label clinical trial. Int. J. Gen. Med. 2021, 14, 2807. [Google Scholar] [CrossRef] [PubMed]
- Onal, H.; Arslan, B.; Ergun, N.U.; Topuz, S.; Semerci, S.Y.; Kurnaz, M.; Bolu, Y.; Bozkurt, M.; Suner, N.; Kocatas, A. Treatment of COVID-19 patients with quercetin: A prospective, single-centre, randomized, controlled trial. Authorea Prepr. 2021, 45, 518–529. [Google Scholar]
- Di Pierro, F.; Derosa, G.; Maffioli, P.; Bertuccioli, A.; Togni, S.; Riva, A. Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: A prospective, randomized, controlled, and open-label study. Int. J. Gen. Med. 2021, 14, 2359. [Google Scholar] [CrossRef]
- Manjunath, S.H.; Thimmulappa, R.K. Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: Potential role in prevention and management of COVID-19. J. Pharm. Anal. 2021, 12, 29–34. [Google Scholar] [CrossRef]
- D’Andrea, G. Quercetin: A flavonol with multifaceted therapeutic applications? Fitoterapia 2015, 106, 256–271. [Google Scholar] [CrossRef]
- Alrawaiq, N.S.; Abdullah, A. A review of flavonoid quercetin: Metabolism, bioactivity and antioxidant properties. Int. J. PharmTech Res. 2014, 6, 933–941. [Google Scholar]
- Taşlıdere, E.; Doğan, Z.; Elbe, H.; Vardı, N.; Çetin, A.; Türköz, Y. Quercetin Protection against Ciprofloxacin Induced Liver Damage in Rats. Biotech. Histochem. 2016, 91, 116–121. [Google Scholar] [CrossRef]
- Ullah, A.; Munir, S.; Badshah, S.L.; Khan, N.; Ghani, L.; Poulson, B.G.; Emwas, A.H.; Jaremko, M. Important flavonoids and their role as a therapeutic agent. Molecules 2020, 25, 5243. [Google Scholar] [CrossRef]
- Heinz, S.A.; Henson, D.A.; Austin, M.D.; Jin, F.; Nieman, D.C. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol. Res. 2010, 62, 237–242. [Google Scholar] [CrossRef] [PubMed]
- Rathinavel, T.; Meganathan, B.; Kumarasamy, S.; Ammashi, S.; Thangaswamy, S.; Ragunathan, Y.; Palanisamy, S. Potential COVID-19 drug from natural phenolic compounds through in silico virtual screening approach. Biointerface Res. Appl. Chem. 2020, 11, 10161–10173. [Google Scholar]
- Clinicaltrials.gov. Quercetine and COVID19. Available online: https://clinicaltrials.gov/ct2/results?term=quercetin&cond=covid+19&Search=Apply&recrs=e&age_v=&gndr=&type=&rslt= (accessed on 26 September 2022).
- Khan, A.; Iqtadar, S.; Mumtaz, S.U.; Heinrich, M.; Pascual-Figal, D.A.; Livingstone, S.; Abaidullah, S. Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial. Front. Pharmacol. 2022, 13, 898062. [Google Scholar] [CrossRef] [PubMed]
- Shohan, M.; Nashibi, R.; Mahmoudian-Sani, M.-R.; Abolnezhadian, F.; Ghafourian, M.; Alavi, S.M.; Sharhani, A.; Khodadadi, A. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial. Eur. J. Pharmacol. 2022, 914, 174615. [Google Scholar] [CrossRef]
- Liu, Z.; Ying, Y. The inhibitory effect of curcumin on virus-induced cytokine storm and its potential use in the associated severe pneumonia. Front. Cell Dev. Biol. 2020, 8, 479. [Google Scholar] [CrossRef]
- Araujo, C.; Leon, L. Biological activities of Curcuma longa L. Memórias Do Inst. Oswaldo Cruz 2001, 96, 723–728. [Google Scholar] [CrossRef]
- Xu, X.-Y.; Meng, X.; Li, S.; Gan, R.-Y.; Li, Y.; Li, H.-B. Bioactivity, health benefits, and related molecular mechanisms of curcumin: Current progress, challenges, and perspectives. Nutrients 2018, 10, 1553. [Google Scholar] [CrossRef] [Green Version]
- Ardebili, A.; Pouriayevali, M.H.; Aleshikh, S.; Zahani, M.; Ajorloo, M.; Izanloo, A.; Siyadatpanah, A.; Nikoo, H.R.; Wilairatana, P.; Coutinho, H.D.M. Antiviral therapeutic potential of curcumin: An update. Molecules 2021, 26, 6994. [Google Scholar] [CrossRef]
- Shanmugarajan, D.; Prabitha, P.; Kumar, B.P.; Suresh, B. Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors: Computational modelling, simulations, and ADMET studies to explore curcuminoids against novel SARS-CoV-2 targets. RSC Adv. 2020, 10, 31385–31399. [Google Scholar] [CrossRef]
- Rocha, F.; de Assis, M. Turmeric against Covid-19: Too much of a coincidence? Authorea Prepr. 2020. [Google Scholar]
- Saber-Moghaddam, N.; Salari, S.; Hejazi, S.; Amini, M.; Taherzadeh, Z.; Eslami, S.; Rezayat, S.M.; Jaafari, M.R.; Elyasi, S. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial. Phytother. Res. 2021, 35, 2616–2623. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Meena, A.; Luqman, S. Baicalin mediated regulation of key signaling pathways in cancer. Pharmacol. Res. 2021, 164, 105387. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.; Du, Q. Potential Natural Compounds for Preventing SARS-CoV-2 (2019-nCoV) Infection. Preprints 2020, 2020010358. [Google Scholar] [CrossRef] [Green Version]
- Lin, C.; Tsai, F.-J.; Hsu, Y.-M.; Ho, T.-J.; Wang, G.-K.; Chiu, Y.-J.; Ha, H.A.; Yang, Y.S. Study of baicalin toward COVID-19 Treatment: In silico target analysis and in vitro inhibitory effects on SARS-CoV-2 proteases. Biomed. Hub 2021, 6, 122–137. [Google Scholar] [CrossRef] [PubMed]
- Chen, F.; Chan, K.; Jiang, Y.; Kao, R.; Lu, H.; Fan, K.; Cheng, V.C.C.; Tsui, W.H.W.; Hung, I.F.N.; Lee, T.S.W. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J. Clin. Virol. 2004, 31, 69–75. [Google Scholar] [CrossRef] [PubMed]
- Li, K.; Liang, Y.; Cheng, A.; Wang, Q.; Li, Y.; Wei, H.; Zhou, C.; Wan, X. Antiviral properties of baicalin: A concise review. Rev. Bras. De Farmacogn. 2021, 31, 408–419. [Google Scholar] [CrossRef] [PubMed]
- Calderon-Montano, J.M.; Burgos-Morón, E.; Pérez-Guerrero, C.; López-Lázaro, M. A review on the dietary flavonoid kaempferol. Mini Rev. Med. Chem. 2011, 11, 298–344. [Google Scholar] [CrossRef] [PubMed]
- Jeong, H.J.; Ryu, Y.B.; Park, S.-J.; Kim, J.H.; Kwon, H.-J.; Kim, J.H.; Park, K.H.; Rho, M.-C.; Lee, W.S. Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorganic Med. Chem. 2009, 17, 6816–6823. [Google Scholar] [CrossRef] [PubMed]
- Behbahani, M.; Sayedipour, S.; Pourazar, A.; Shanehsazzadeh, M. In vitro anti-HIV-1 activities of kaempferol and kaempferol-7-O-glucoside isolated from Securigera securidaca. Res. Pharm. Sci. 2014, 9, 463. [Google Scholar]
- Khaerunnisa, S.; Kurniawan, H.; Awaluddin, R.; Suhartati, S.; Soetjipto, S. Potential inhibitor of COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular docking study. Preprints 2020, 2020, 2020030226. [Google Scholar]
- Pandey, P.; Rane, J.S.; Chatterjee, A.; Kumar, A.; Khan, R.; Prakash, A.; Ray, S. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: An in silico study for drug development. J. Biomol. Struct. Dyn. 2021, 39, 6306–6316. [Google Scholar] [CrossRef] [PubMed]
- Zhu, L.; Wang, P.; Yuan, W.; Zhu, G. Kaempferol inhibited bovine herpesvirus 1 replication and LPS-induced inflammatory response. Acta Virol. 2018, 62, 220–225. [Google Scholar] [CrossRef]
- Ali, A.S.; Saied, E.A.; Theeban, S.M.; Humayran, M.M.; Shaker, A.A.; Alfadil, A.; Almuhayawi, M.S. Phytochemicals against COVID -19, Pharmacological Perspectives: A Systematic Review. J. Pharm. Res. Int. 2021, 33, 34–55. [Google Scholar]
- Di Matteo, G.; Spano, M.; Grosso, M.; Salvo, A.; Ingallina, C.; Russo, M.; Ritieni, A.; Mannina, L. Food and COVID-19: Preventive/co-therapeutic strategies explored by current clinical trials and in silico studies. Foods 2020, 9, 1036. [Google Scholar] [CrossRef] [PubMed]
- Behl, T.; Rocchetti, G.; Chadha, S.; Zengin, G.; Bungau, S.; Kumar, A.; Mehta, V.; Uddin, M.S.; Khullar, G.; Setia, D. Phytochemicals from plant foods as potential source of antiviral agents: An overview. Pharmaceuticals 2021, 14, 381. [Google Scholar] [CrossRef]
- Ramdani, L.; Bachari, K. Potential therapeutic effects of Resveratrol against SARS-CoV-2. Acta Virol. 2020, 64, 276–280. [Google Scholar] [CrossRef] [PubMed]
- Abba, Y.; Hassim, H.; Hamzah, H.; Noordin, M.M. Antiviral activity of resveratrol against human and animal viruses. Adv. Virol. 2015, 2015, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pasquereau, S.; Nehme, Z.; Haidar Ahmad, S.; Daouad, F.; Van Assche, J.; Wallet, C.; Schwartz, C.; Rohr, O.; Morot-Bizot, S.; Herbein, G. Resveratrol inhibits HCoV-229E and SARS-CoV-2 coronavirus replication in vitro. Viruses 2021, 13, 354. [Google Scholar] [CrossRef]
- Filardo, S.; Di Pietro, M.; Mastromarino, P.; Sessa, R. Therapeutic potential of resveratrol against emerging respiratory viral infections. Pharmacol. Ther. 2020, 214, 107613. [Google Scholar] [CrossRef]
- Wahedi, H.M.; Ahmad, S.; Abbasi, S.W. Stilbene-based natural compounds as promising drug candidates against COVID-19. J. Biomol. Struct. Dyn. 2021, 39, 3225–3234. [Google Scholar] [CrossRef]
- Yang, M.; Wei, J.; Huang, T.; Lei, L.; Shen, C.; Lai, J.; Yang, M.; Liu, L.; Yang, Y.; Liu, G. Resveratrol inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells. Phytother. Res. 2021, 35, 1127–1129. [Google Scholar] [CrossRef] [PubMed]
- Chimento, A.; De Amicis, F.; Sirianni, R.; Sinicropi, M.S.; Puoci, F.; Casaburi, I.; Saturnino, C.; Pezzi, V. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int. J. Mol. Sci. 2019, 20, 1381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Zhang, H.; Chen, L.; Shan, L.; Fan, G.; Gao, X. Liquorice, a unique “guide drug” of traditional Chinese medicine: A review of its role in drug interactions. J. Ethnopharmacol. 2013, 150, 781–790. [Google Scholar] [CrossRef] [PubMed]
- Diomede, L.; Beeg, M.; Gamba, A.; Fumagalli, O.; Gobbi, M.; Salmona, M. Can antiviral activity of licorice help fight COVID-19 infection? Biomolecules 2021, 11, 855. [Google Scholar] [CrossRef]
- Gomaa, A.A.; Abdel-Wadood, Y.A. The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions. Phytomedicine Plus 2021, 1, 100043. [Google Scholar] [CrossRef]
- Bailly, C.; Vergoten, G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol. Ther. 2020, 214, 107618. [Google Scholar] [CrossRef]
- Lee, D.Y.; Li, Q.Y.; Liu, J.; Efferth, T. Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. Phytomedicine 2021, 80, 153337. [Google Scholar] [CrossRef]
- Hoever, L.B.G.; Michaelis, M.; Kondratenko, R.; Baltina, L.; Tolstikov, G.A.; Doerr, H.W.; Cinatl, J. Antiviral Activity of Glycyrrhizic Acid Derivatives against SARS−Coronavirus. J. Med. Chem. 2005, 48, 1256–1259. [Google Scholar] [CrossRef]
- Khalifa, M.F.; Attia, E.Z.; Fahim, J.R.; Kamel, M.S. An overview on the chemical and biological aspects of lycorine alkaloid. J. Adv. Biomed. Pharm. Sci. 2018, 1, 41–49. [Google Scholar] [CrossRef]
- Cao, Z.; Yang, P.; Zhou, Q. Multiple biological functions and pharmacological effects of lycorine. Sci. China Chem. 2013, 56, 1382–1391. [Google Scholar] [CrossRef]
- Zhang, Y.-N.; Zhang, Q.-Y.; Li, X.-D.; Xiong, J.; Xiao, S.-Q.; Wang, Z.; Zhang, Z.-R.; Deng, C.-L.; Yang, X.-L.; Wei, H.-P. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture. Emerg. Microbes Infect. 2020, 9, 1170–1173. [Google Scholar] [CrossRef] [PubMed]
- Jin, Y.-H.; Min, J.S.; Jeon, S.; Lee, J.; Kim, S.; Park, T.; Park, D.; Jang, M.S.; Park, C.M.; Song, J.H. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections. Phytomedicine 2021, 86, 153440. [Google Scholar] [CrossRef] [PubMed]
- Slobodnick, A.; Shah, B.; Pillinger, M.H.; Krasnokutsky, S. Colchicine: Old and new. Am. J. Med. 2015, 128, 461–470. [Google Scholar] [CrossRef] [PubMed]
- Akram, M.; Alam, O.; Usmanghani, K.; Akhter, N.; Asif, H. Colchicum autumnale: A review. J. Med. Plants Res. 2012, 6, 1489–1491. [Google Scholar] [CrossRef]
- Schlesinger, N.; Firestein, B.L.; Brunetti, L. Colchicine in COVID-19: An old drug, new use. Curr. Pharmacol. Rep. 2020, 6, 137–145. [Google Scholar] [CrossRef]
- Drosos, A.A.; Pelechas, E.; Drossou, V.; Voulgari, P.V. Colchicine against SARS-CoV-2 infection: What is the evidence? Rheumatol. Ther. 2022, 9, 379–389. [Google Scholar] [CrossRef]
- Montealegre-Gómez, G.; Garavito, E.; Gómez-López, A.; Rojas-Villarraga, A.; Parra-Medina, R. Colchicine: A potential therapeutic tool against COVID-19. Exp. 5 Patients. Reumatol. Clínica 2021, 17, 371–375. [Google Scholar] [CrossRef]
- Vitiello, A.; Ferrara, F. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state. Respir. Med. 2021, 178, 106322. [Google Scholar] [CrossRef]
- Clinicaltrials.gov. Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19). Available online: https://clinicaltrials.gov/ct2/show/results/NCT04322682?term=04322682&cond=sars+cov+2&draw=2&view=results (accessed on 27 September 2022).
- Kapepula, P.M.; Kabengele, J.K.; Kingombe, M.; Van Bambeke, F.; Tulkens, P.M.; Kishabongo, A.S.; Nachega, J.B. Artemisia Spp. derivatives for COVID-19 treatment: Anecdotal use, political hype, treatment potential, challenges, and road map to randomized clinical trials. Am. J. Trop. Med. Hyg. 2020, 103, 960. [Google Scholar] [CrossRef]
- Shi, C.; Li, H.; Yang, Y.; Hou, L. Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives. Mediat. Inflamm. 2015, 2015, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Cao, R.; Hu, H.; Li, Y.; Wang, X.; Xu, M.; Liu, J.; Zhong, W. Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect. Dis. 2020, 6, 2524–2531. [Google Scholar] [CrossRef] [PubMed]
- Nair, M.S.; Huang, Y.; Fidock, D.A.; Polyak, S.J.; Wagoner, J.; Towler, M.J.; Weathers, P.J. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants. J. Ethnopharmacol. 2021, 274, 114016. [Google Scholar] [CrossRef]
- Hunt, S.; Yoshida, M.; Davis, C.E.; Greenhill, N.S.; Davis, P.F. An extract of the medicinal plant Artemisia annua modulates production of inflammatory markers in activated neutrophils. J. Inflamm. Res. 2015, 8, 9. [Google Scholar] [CrossRef] [PubMed]
- Li, G.; Yuan, M.; Li, H.; Deng, C.; Wang, Q.; Tang, Y.; Song, J. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: An open-label, non-randomised and controlled trial. Int. J. Antimicrob. Agents 2021, 57, 106216. [Google Scholar] [CrossRef]
- Xiao, T.; Cui, M.; Zheng, C.; Wang, M.; Sun, R.; Gao, D.; Zhou, H. Myricetin inhibits SARS-CoV-2 viral replication by targeting Mpro and ameliorates pulmonary inflammation. Front. Pharmacol. 2021, 12, 1012. [Google Scholar] [CrossRef] [PubMed]
- Farhat, A.; Ben Hlima, H.; Khemakhem, B.; Ben Halima, Y.; Michaud, P.; Abdelkafi, S.; Fendri, I. Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach. Bioengineered 2022, 13, 3350–3361. [Google Scholar] [CrossRef] [PubMed]
- Shawan, M.M.A.K.; Halder, S.K.; Hasan, M. Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: An in silico molecular modeling approach in battling the COVID-19 outbreak. Bull. Natl. Res. Cent. 2021, 45, 1–21. [Google Scholar] [CrossRef] [PubMed]
- Ghosh, R.; Chakraborty, A.; Biswas, A.; Chowdhuri, S. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors–an in silico docking and molecular dynamics simulation study. J. Biomol. Struct. Dyn. 2021, 39, 4362–4374. [Google Scholar] [CrossRef]
- Oso, B.J.; Adeoye, A.O.; Olaoye, I.F. Pharmacoinformatics and hypothetical studies on allicin, curcumin, and gingerol as potential candidates against COVID-19-associated proteases. J. Biomol. Struct. Dyn. 2022, 40, 389–400. [Google Scholar] [CrossRef]
- Altyar, A.E.; Youssef, F.S.; Kurdi, M.M.; Bifari, R.J.; Ashour, M.L. The Role of Cannabis sativa L. as a Source of Cannabinoids against Coronavirus 2 (SARS-CoV-2): An In Silico Study to Evaluate Their Activities and ADMET Properties. Molecules 2022, 27, 2797. [Google Scholar] [CrossRef]
- Shekh, S.; Reddy, K.K.A.; Gowd, K.H. In silico allicin induced S-thioallylation of SARS-CoV-2 main protease. J. Sulfur Chem. 2021, 42, 109–120. [Google Scholar] [CrossRef]
- Shree, P.; Mishra, P.; Selvaraj, C.; Singh, S.K.; Chaube, R.; Garg, N.; Tripathi, Y.B. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants–Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi)–a molecular docking study. J. Biomol. Struct. Dyn. 2022, 40, 190–203. [Google Scholar] [CrossRef] [PubMed]
- Karimi, M.; Zarei, A.; Soleymani, S.; Jamalimoghadamsiahkali, S.; Asadi, A.; Shati, M.; Jafari, M.; Rezadoost, H.; Kordafshar, G.; Naghizadeh, A. Efficacy of Persian medicine herbal formulations (capsules and decoction) compared to standard care in patients with COVID-19, a multicenter open-labeled, randomized, controlled clinical trial. Phytother. Res. 2021, 35, 6295–6309. [Google Scholar] [CrossRef] [PubMed]
- Koshak, A.E.; Koshak, E.A.; Mobeireek, A.F.; Badawi, M.A.; Wali, S.O.; Malibary, H.M.; Atwah, A.F.; Alhamdan, M.M.; Almalki, R.A.; Madani, T.A. Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial. Complementary Ther. Med. 2021, 61, 102769. [Google Scholar] [CrossRef] [PubMed]
- Ashraf, S.; Ashraf, S.; Ashraf, M.; Imran, M.A.; Kalsoom, L.; Siddiqui, U.N.; Farooq, I.; Habib, Z.; Ashraf, S.; Ghufran, M. Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial. MedRxiv 2020. [Google Scholar]
- Silveira, M.A.D.; De Jong, D.; Berretta, A.A.; dos Santos Galvão, E.B.; Ribeiro, J.C.; Cerqueira-Silva, T.; Amorim, T.C.; Rebelo da Conceição, L.F.M.; Gomes, M.M.D.; Teixeira, M.B. Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial. Biomed. Pharmacother. 2021, 138, 111526. [Google Scholar] [CrossRef]
- Balmforth, D.; Swales, J.A.; Silpa, L.; Dunton, A.; Davies, K.E.; Davies, S.G.; Kamath, A.; Gupta, J.; Gupta, S.; Masood, M.A. Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial. J. Clin. Virol. 2022, 155, 105248. [Google Scholar] [CrossRef]
- Asif, M.; Saleem, M.; Saadullah, M.; Yaseen, H.S.; Al Zarzour, R. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. Inflammopharmacology 2020, 28, 1153–1161. [Google Scholar] [CrossRef]
- Zengli, L.; Xiuhui, L.; Chunyan, G.; Li, L.; Xiaolan, L.; Chun, Z.; Xiaojun, W. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients. J. Tradit. Chin. Med. 2020, 40, 467. [Google Scholar]
- Shi, M.; Peng, B.; Li, A.; Li, Z.; Song, P.; Li, J.; Li, N. Broad Anti-viral capacities of Lian-Hua-Qing-Wen capsule and Jin-Hua-Qing-Gan granule and rational use against COVID-19 based on literature mining. Front. Pharmacol. 2021, 12, 640782. [Google Scholar] [CrossRef]
- Wen, L.; Zhou, Z.; Jiang, D.; Huang, K. Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020, 2, 426–429. [Google Scholar]
Active Compound | Source | Structure of SARS-CoV-2 Considered Targeted by Given Phytochemicals | References |
---|---|---|---|
myrcetin | in most fruits, vegetables, tea and wine | SARS-CoV-2 3Clpro | [108] |
apigenin | in many fruits and vegetables, in plants such as Petroselinum crispum, Apiaceae and Matricaria chamomila, Asteraceae | SARS-CoV-2 3Clpro | [109] |
luteolin | vegetables and fruits such as celery, parsley, broccoli, onion leaves, carrots, peppers, cabbages andapple | SARS-CoV-2 3Clpro, PL-pro and ACE2 | [110] |
abyssinone II | Chinese medicinal plant Broussonetia papyrifera, Moraceae | SARS-CoV-2 3Clpro, PL-pro and ACE2 | [110] |
green tea polyphenols | green tea | SARS-CoV-2 3Clpro | [111] |
gingerol | Zingiber officinale, Zingiberaceae | SARS-CoV-2 3Clpro | [112] |
cannabidiol | Cannabis sativa, Cannabaceae | SARS-CoV-2 3Clpro, PL-pro and ACE2 | [113] |
allicin | Allium sativum, Amaryllidaceae | SARS-CoV-2 3Clpro | [114] |
withanoside V and somniferine | Withania somnifera, Solanaceae (Ashwagandha) | SARS-CoV-2 3Clpro | [115] |
tinocordiside | Tinospora cordifolia, Menispermaceae | SARS-CoV-2 3Clpro | [115] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bijelić, K.; Hitl, M.; Kladar, N. Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence. Antibiotics 2022, 11, 1614. https://doi.org/10.3390/antibiotics11111614
Bijelić K, Hitl M, Kladar N. Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence. Antibiotics. 2022; 11(11):1614. https://doi.org/10.3390/antibiotics11111614
Chicago/Turabian StyleBijelić, Katarina, Maja Hitl, and Nebojša Kladar. 2022. "Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence" Antibiotics 11, no. 11: 1614. https://doi.org/10.3390/antibiotics11111614